ArticleProbiotics and antimicrobial proteins2024
Safety Evaluation of a Novel Potentially Probiotic Limosilactobacillus fermentum in Rats.
Article in Probiotics and antimicrobial proteins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Safety and immunostimulatory potential evaluation of Limosilactobacillus fermentum isolated from millet-based fermented food in mice.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Investigating the release of the bioactive components of novel nutraceuticals combining potentially probiotic Limosilactobacillus fermentum and freeze-dried jabuticaba peel during gastrointestinal digestion for long-term storage.Probiotics and antimicrobial proteins · 2026Article
- Synbiotic Nutraceutical Mitigates Gestational Diabetes Effects and Cardiovascular Dysfunction in Rat Offspring.Molecular nutrition & food research · 2026Article
- Antibacterial and Anti-virulence Properties of Cell-free Supernatant from a Mixture of Limosilactobacillus fermentum Strains Against Enterotoxigenic Escherichia coli.Probiotics and antimicrobial proteins · 2025Article
- Thermal and storage stability of novel nutraceuticals combining potential probiotic Limosilactobacillus fermentum strains and freeze-dried jabuticaba [Myrciaria cauliflora (Mart.) O. Berg] peel.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Randomized Clinical Trials Demonstrate the Safety Assessment ofMicroorganisms · 2024Article
- Limosilactobacillus fermentum Strains as Novel Probiotic Candidates to Promote Host Health Benefits and Development of Biotherapeutics: A Comprehensive Review.Probiotics and antimicrobial proteins · 2024Review
- A Mix of Potentially ProbioticMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limosilactobacillus (L) fermentum (strains 139, 263, 296) is a novel probiotic mixture isolated from fruit processing by-products. The use of this formulation has been associated with improvements in cardiometabolic, inflammatory, and oxidative stress parameters. The present study evaluated the safety of a potential multi-strain probiotic by genotoxicity (micronucleus assay) and subchronic toxicity study (13-week repeated dose). In the genotoxicity evaluation, L. fermentum 139, 263, 296 did not increase the frequency of micronuclei in erythrocytes of rats of both sexes at doses up to 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.